Pfizer (PFE) executive says obesity study results increase significantly Co's confidence in Phase 3 monthly dosing study set to launch this year; targeting the first of a series of potential obesity approvals in 2028
Importance
Level 1
#PFIZER INC#PFE.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#US EQUITIES